Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2015 1
2016 2
2017 3
2019 2
2020 6
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.
Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S. Hwang I, et al. Drug Des Devel Ther. 2020 Oct 23;14:4493-4502. doi: 10.2147/DDDT.S275336. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33122892 Free PMC article. Clinical Trial.
AIM: Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. ...All subjects received evogliptin 5 mg once daily for 7 days (EVO), pioglitazone 30 mg once daily for 7 days ( …
AIM: Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type …
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.
Moon JS, Park IR, Kim HJ, Chung CH, Won KC, Han KA, Park CY, Won JC, Kim DJ, Koh GP, Kim ES, Yu JM, Hong EG, Lee CB, Yoon KH. Moon JS, et al. Diabetes Metab J. 2023 Nov;47(6):808-817. doi: 10.4093/dmj.2022.0387. Epub 2023 Sep 26. Diabetes Metab J. 2023. PMID: 37750183 Free PMC article. Clinical Trial.
BACKGRUOUND: This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination. ...Adverse events were simil …
BACKGRUOUND: This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately con …
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Yoo H, Kim Y, Jang IJ, Yu KS, Lee S. Yoo H, et al. Drug Des Devel Ther. 2020 Nov 24;14:5179-5187. doi: 10.2147/DDDT.S275343. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33262578 Free PMC article. Clinical Trial.
Glucose excursion decreased with the co-administration of evogliptin and glimepiride compared with that observed with the evogliptin or glimepiride monotherapy. CONCLUSION: Evogliptin and glimepiride had no PK interactions when co-administered, while the comb …
Glucose excursion decreased with the co-administration of evogliptin and glimepiride compared with that observed with the evoglipt …
The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis.
Tang Q, Pan W, Peng L. Tang Q, et al. Front Endocrinol (Lausanne). 2022 Aug 19;13:962385. doi: 10.3389/fendo.2022.962385. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36060938 Free PMC article.
Thus, the aim was to evaluate the overall influence of evogliptin on HbA1c levels and the adverse events in T2DM patients compared to sitagliptin and linagliptin. ...P = 0.966) regarding the adverse effects, indicating no significant difference between evogliptin an …
Thus, the aim was to evaluate the overall influence of evogliptin on HbA1c levels and the adverse events in T2DM patients compared to …
Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System.
Oh H, Nguyen HD, Yoon IM, Kim MS. Oh H, et al. Clin Ther. 2021 Aug;43(8):1336-1355. doi: 10.1016/j.clinthera.2021.06.001. Epub 2021 Jul 22. Clin Ther. 2021. PMID: 34304912 Free article.
PURPOSE: Evogliptin is one of the latest dipeptidyl peptidase-4 (DPP-4) inhibitor, and a number of clinical trials have been performed following its development, including several randomized controlled trials (RCTs) performed to evaluate its efficacy and tolerability. ...F …
PURPOSE: Evogliptin is one of the latest dipeptidyl peptidase-4 (DPP-4) inhibitor, and a number of clinical trials have been performe …
Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).
Kim G, Lim S, Kwon HS, Park IB, Ahn KJ, Park CY, Kwon SK, Kim HS, Park SW, Kim SG, Moon MK, Kim ES, Chung CH, Park KS, Kim M, Chung DJ, Lee CB, Kim TH, Lee MK. Kim G, et al. Diabetes Obes Metab. 2020 Sep;22(9):1527-1536. doi: 10.1111/dom.14061. Epub 2020 May 29. Diabetes Obes Metab. 2020. PMID: 32319168 Free PMC article. Clinical Trial.
In the extension study conducted during the following 12 weeks, evogliptin 5 mg daily was administered to both groups: evogliptin/evogliptin group (n = 95) and linagliptin/evogliptin group (n = 92). ...However, they did not differ significantly between …
In the extension study conducted during the following 12 weeks, evogliptin 5 mg daily was administered to both groups: evogliptin …
Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
Ajmani AK, Agrawal A, Prasad BLN, Basu I, Shembalkar J, Manikanth N, Subrahmanyam KAV, Srinivasa M, Chawla M, Srivastava MK, Jebasingh F, Achappa B, Agrawal RP, Pulichikkat RK, Meena R, Bhatia S, Gupta SK, Dange A, Srivastava A, Trailokya A, Shahavi V, Shende S. Ajmani AK, et al. Diabetes Res Clin Pract. 2019 Nov;157:107860. doi: 10.1016/j.diabres.2019.107860. Epub 2019 Sep 14. Diabetes Res Clin Pract. 2019. PMID: 31526825 Clinical Trial.

Patients achieving target HbA(1c) < 7.0% (evogliptin, 26.7% vs. sitagliptin, 20%) was almost equal in both groups. Treatment-emergent adverse events occured in 52 patients (evogliptin, 25% and sitagliptin, 31.5%) and were generally mild. CONCLUSIONS: Evoglipti

…

Patients achieving target HbA(1c) < 7.0% (evogliptin, 26.7% vs. sitagliptin, 20%) was almost equal in both groups. Treatment-emerg

…
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
Park J, Park SW, Yoon KH, Kim SR, Ahn KJ, Lee JH, Mok JO, Chung CH, Han KA, Koh GP, Kang JG, Lee CB, Kim SH, Kwon NY, Kim DM. Park J, et al. Diabetes Obes Metab. 2017 Dec;19(12):1681-1687. doi: 10.1111/dom.12987. Epub 2017 Jul 7. Diabetes Obes Metab. 2017. PMID: 28448688 Free PMC article. Clinical Trial.
RESULTS: The mean baseline HbA1c levels were similar in the evogliptin and the placebo groups (7.20% 0.56% vs 7.20% 0.63%, respectively). At week 24, evogliptin significantly reduced HbA1c levels from baseline compared with placebo (-0.23% vs 0.05%, respectively, P …
RESULTS: The mean baseline HbA1c levels were similar in the evogliptin and the placebo groups (7.20% 0.56% vs 7.20% 0.63%, respective …
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS. Gu N, et al. Drug Des Devel Ther. 2014 Oct 6;8:1709-21. doi: 10.2147/DDDT.S65678. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25336915 Free PMC article. Clinical Trial.
Subjects in each group were randomized to receive evogliptin or placebo with a ratio of 8:2. Pharmacokinetics of evogliptin were evaluated, with its concentrations in serial plasma and urine samples collected following the first and last administrations. ...A once-d …
Subjects in each group were randomized to receive evogliptin or placebo with a ratio of 8:2. Pharmacokinetics of evogliptin we …
Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Hong SM, Park CY, Hwang DM, Han KA, Lee CB, Chung CH, Yoon KH, Mok JO, Park KS, Park SW. Hong SM, et al. Diabetes Obes Metab. 2017 May;19(5):654-663. doi: 10.1111/dom.12870. Epub 2017 Feb 22. Diabetes Obes Metab. 2017. PMID: 28058750 Free PMC article. Clinical Trial.

After the 52-week treatment, evogliptin caused a persistently decreased level of HbA1c (-0.44% 0.65%, P < .0001). ...Hypoglycaemic events, mostly mild, were reported in 0.9% of patients treated with evogliptin and in 2.8% of patients treated with sitagliptin for

…

After the 52-week treatment, evogliptin caused a persistently decreased level of HbA1c (-0.44% 0.65%, P < .0001). ...Hypoglycaemic

…
21 results